Novartis AG ADR (NVS)vsVivos Therapeutics Inc (VVOS)
NVS
Novartis AG ADR
$148.38
-0.96%
HEALTHCARE · Cap: $273.77B
VVOS
Vivos Therapeutics Inc
$0.86
+24.84%
HEALTHCARE · Cap: $8.53M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 289035% more annual revenue ($56.58B vs $19.57M). NVS leads profitability with a 23.9% profit margin vs -127.7%. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
VVOS
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Margin of Safety
+26.5%
Fair Value
$2.11
Current Price
$0.86
$1.25 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Revenue surging 70.5% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -1600.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : VVOS
The strongest argument for VVOS centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 70.5% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : VVOS
The primary concerns for VVOS are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
NVS profiles as a declining stock while VVOS is a hypergrowth play — different risk/reward profiles.
VVOS carries more volatility with a beta of 6.08 — expect wider price swings.
VVOS is growing revenue faster at 70.5% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 31/100), backed by strong 23.9% margins. VVOS offers better value entry with a 26.5% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Vivos Therapeutics Inc
HEALTHCARE · MEDICAL DEVICES · USA
Vivos Therapeutics, Inc., a medical technology company, is dedicated to developing and commercializing treatment alternatives for patients with sleep-disordered breathing, such as mild to moderate obstructive sleep apnea (OSA). The company is headquartered in Highlands Ranch, Colorado.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?